Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $2.00 at Maxim Group

Reviva Pharmaceuticals (NASDAQ:RVPH) had its price objective trimmed by Maxim Group from $5.00 to $2.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also issued reports on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $3.00 target price on shares of Reviva Pharmaceuticals in a research note on Friday, June 27th. Citigroup reissued a “buy” rating on shares of Reviva Pharmaceuticals in a research note on Friday. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Reviva Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $8.00.

Reviva Pharmaceuticals Price Performance

Shares of RVPH opened at $0.54 on Friday. The firm has a market cap of $25.92 million, a P/E ratio of -0.83 and a beta of -0.05. The stock has a 50 day simple moving average of $0.51 and a two-hundred day simple moving average of $0.90. Reviva Pharmaceuticals has a 1 year low of $0.30 and a 1 year high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03. On average, equities analysts anticipate that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ameriprise Financial Inc. bought a new position in shares of Reviva Pharmaceuticals during the fourth quarter valued at approximately $84,000. Tower Research Capital LLC TRC raised its holdings in shares of Reviva Pharmaceuticals by 848.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after acquiring an additional 23,953 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Reviva Pharmaceuticals by 11.9% during the fourth quarter. Geode Capital Management LLC now owns 311,701 shares of the company’s stock valued at $564,000 after acquiring an additional 33,205 shares in the last quarter. Cornerstone Select Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the fourth quarter valued at approximately $32,000. Finally, BluePointe Capital Management LLC raised its holdings in shares of Reviva Pharmaceuticals by 354.7% during the first quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock valued at $45,000 after acquiring an additional 36,807 shares in the last quarter. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.